These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Intravitreal ranibizumab for age-related macular degeneration].
    Author: Sørensen TL, Kemp H.
    Journal: Ugeskr Laeger; 2010 May 31; 172(22):1685-9. PubMed ID: 20525469.
    Abstract:
    INTRODUCTION: Ranibizumab has improved visual prognosis for patients with age-related macula degeneration (ARMD) complicated with choroidal neovascularisation. We evaluated the results of all our patients within a two-year period. MATERIAL AND METHODS: A total of 647 eyes have so far been treated. In all 2,735 injections have been performed. RESULTS: Ranibizumab initially increased significantly the best corrected visual acuity from 0.29 to 0.35 (p < 0.001), but after six and 12 months visual acuity stabilized (p = 0.1). We found a positive correlation between initial visual acuity and final visual acuity (p < 0.001). There was a negative correlation between age and final visual acuity (p < 0.001). Complications were rare: one got cataract, we observed a retinal detachment and one choroidal detachment. Other complications were rare and mild. CONCLUSION: Ranibizumab improves visual prognosis in exudative ARMD. Intravitreal injections are safe and complications are rare.
    [Abstract] [Full Text] [Related] [New Search]